TransMedics (TMDX) EBITDA (2018 - 2026)

TransMedics' EBITDA history runs 9 years deep, the most recent figure standing at $13.3 million for Q1 2026.

• On a quarterly basis, EBITDA fell 51.55% year-over-year to $13.3 million in Q1 2026; TTM through Mar 2026 was $94.4 million, a 79.82% increase from a year earlier, with the FY2025 full-year figure at $108.6 million, up 189.59% from the prior year.
• EBITDA fell to $13.3 million in Q1 2026 per TMDX's latest filing, from $21.3 million in the prior quarter.
• Across five years, EBITDA topped out at $36.6 million in Q2 2025 and bottomed at -$28.3 million in Q3 2023.
• The 5-year median for EBITDA is $3.9 million (2024), against an average of $5.8 million.
• Across the five-year window, EBITDA sank 411.09% in 2023 and soared 1480.57% in 2024, its largest moves.
• Year by year, EBITDA stood at -$6.8 million in 2022, then soared by 138.4% to $2.6 million in 2023, then soared by 232.08% to $8.6 million in 2024, then soared by 146.1% to $21.3 million in 2025, then sank by 37.49% to $13.3 million in 2026.
• Per Business Quant, the three latest TMDX EBITDA figures stand at $13.3 million (Q1 2026), $21.3 million (Q4 2025), and $23.3 million (Q3 2025).